Core Viewpoint - The company, Zhaoke Ophthalmology-B (06622.HK), has had its registration application for atropine sulfate eye drops (0.01% dosage, product code: NVK002) for treating myopia progression in children accepted by the Australian Therapeutic Goods Administration (TGA) [1] Group 1 - The TGA has officially notified the company that its application has passed the preliminary review and will undergo further evaluation [1] - The application is supported by results from the company's Phase III clinical trials [1] - NVK002 is a novel experimental topical eye solution designed to control myopia progression in children and adolescents [1] Group 2 - NVK002 features a patented formulation that successfully addresses the instability of low-concentration atropine, with intellectual property protection globally [1] - The eye drops are preservative-free and are expected to have a shelf life of over 24 months [1] - According to data from Zhi Shi Consulting, NVK002 is one of the most advanced atropine candidates globally for treating myopia progression, targeting a broad patient group aged 3 to 17 years [1]
兆科眼科-B(06622.HK)：澳洲治疗用品管理局受理评核“硫酸阿托品滴眼液”的注册申请